ClinicalTrials.gg
CompletedNCT04045795Updated Sep 12, 2025

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1 interventional study of isatuximab SAR650984 IV and pomalidomide in Multiple Myeloma, sponsored by Sanofi. Completed at 14 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Enrollment
24th of 50
56 · median 55
Started
2019
the only one that year
Phase 1
10 of 50
none open now
Registered
12th of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 24th largest by enrollment, is the only one that started in 2019, is one of 10 in phase 1, and was the 12th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

Primary Objectives:

  • To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)
  • To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device
  • To evaluate the pharmacokinetics (PK) of SC and IV isatuximab

Secondary Objectives:

  • To estimate absolute bioavailability of SC and IV isatuximab
  • To measure receptor occupancy (RO) after isatuximab SC versus IV administration
  • To assess efficacy of isatuximab after SC and IV administration
  • To assess patient expectations prior to and patient experience and satisfaction after SC administration
  • To evaluate potential immunogenicity of SC or IV isatuximab
Read the detailed description

Total study duration is variable depending on treatment and follow-up periods, including 21 days of screening, and treatment period until disease progression, unacceptable adverse reaction or other reason for discontinuation. End of treatment will be 30 days after last administration of investigational medicinal product, or before further anti-myeloma therapy, whichever comes first; approximately 14 months after first study treatment administration.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  • Participant must be above 18 years of age or country's legal age of majority if the legal age is >18 years old, at the time of signing the informed consent.
  • Participant has been previously diagnosed with multiple myeloma (MM) based on standard criteria and currently requires treatment because MM has following a response, according to International Myeloma Working Group (IMWG) criteria.
  • Participant has received at least two previous therapies including lenalidomide and a proteasome inhibitor and has demonstrated disease progression on last therapy or after completion of the last therapy.
  • Participants with defined as at least one of the following:
  • Serum M protein ≥ 0.5 g/dL (≥5 g/L).
  • Urine M protein ≥ 200 mg/24 hours.
  • Serum free light chain (FLC) assay: Involved FLC assay ≥ 10 mg/dL (≥ 100 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Male or female: use by men or women

Exclusion criteria

Exclusion criteria:

  • within 3 years prior to enrollment.
  • (ECOG) performance status score >2.
  • Inadequate hematological, liver or renal function.
  • Serum calcium (corrected for albumin) level above the (ULN) range.
  • Patients with prior anti-CD38 treatment are excluded if:

    • to anti-CD38 treatment defined as progression on or within 60 days of the last dose of the anti-CD38 or,
    • Intolerant to the anti-CD38 previously received or,
    • Progression after initial response on anti-CD38 therapy with a inferior to 9 months before the first dose of isatuximab SC or IV.
  • Participant did not achieve a minimal response or better to at least one of the (ie, primary refractory disease is not eligible).
  • Received any drug within 14 days or 5 half-lives of the investigational drug, whichever is longer.
  • Prior anti-cancer therapy within 14 days.
  • Any >Grade 1 adverse reaction unresolved from previous treatments according to the v5.0. The presence of alopecia or peripheral neuropathy ≤ Grade 2 without pain is allowed.
  • Previous stem cell transplantation with active or being under therapy in the last 2 months previously to the inclusion in the trial.
  • Daily requirement for .
  • Known to be + or to have hepatitis A or uncontrolled or active virus (HBV) infection (patients with positive HBsAg [HBsAg] and/or HBV DNA) or active (HCV) infection (positive HCV RNA and negative anti-HCV).
  • Active tuberculosis and severe infections requiring treatment with antibiotic parenteral administration.
  • Any , uncontrolled medical conditions that, in the Investigator's opinion, would expose excessive risk to the patient or may interfere with compliance or interpretation of the study results.
  • History of erythema multiforme or severe to prior immunomodulatory drugs (IMiDs).
  • Hypersensitivity or history of intolerance to immunomodulatory drugs (IMiDs), dexamethasone, mannitol, pregelatinized starch, sodium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study therapy that are not amenable to premedication with steroids and histamine H2 blockers or would prohibit further treatment with these agents.
  • Inability to tolerate thromboprophylaxis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Dose regimen 1

    Isatuximab SC administration dose level 1 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle

    Drug: pomalidomide · Drug: dexamethasone · Drug: isatuximab SAR650984 SC

  • Experimental
    Dose regimen 2

    Isatuximab SC administration dose level 2 once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle

    Drug: pomalidomide · Drug: dexamethasone · Drug: isatuximab SAR650984 SC

  • Experimental
    Dose regimen 3

    Isatuximab SC administration dose level 3 using the investigational injector device once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle

    Drug: pomalidomide · Drug: dexamethasone · Drug: isatuximab SAR650984 SC · Device: Investigational injector device

  • Experimental
    Dose regimen 4

    Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle

    Drug: isatuximab SAR650984 IV · Drug: pomalidomide · Drug: dexamethasone

  • Experimental
    Dose regimen 5

    Isatuximab IV administration once weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle

    Drug: isatuximab SAR650984 IV · Drug: pomalidomide · Drug: dexamethasone

Interventions

  • Pharmaceutical form: solution Route of administration: intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: tablet Route of administration: oral

    Also known as: Pomalyst®

  • Pharmaceutical form: tablet Route of administration: oral

    Also known as: Decadron®

  • Drugisatuximab SAR650984 SC

    Pharmaceutical form: solution Route of administration: subcutaneous

  • DeviceInvestigational injector device

    Subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Assessment of adverse events (AEs)

    Number of participants with adverse events

    Time frame: Baseline to 30 days after last study treatment administration (up to approximately 14 months after first study treatment administration)

  2. Pharmacokinetic (PK) assessment: Ceoi

    Concentration observed at the end of infusion (Ceoi)

    Time frame: Baseline to end of treatment (EOT) after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  3. PK assessment: Cmax

    Maximum concentration observed after the first infusion (Cmax)

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  4. PK assessment: tmax

    Time to reach Cmax (tmax)

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  5. PK assessment: Clast

    Last concentration observed above the lower limit of quantification after the first infusion (Clast)

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  6. PK assessment: tlast

    Time of Clast (tlast)

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  7. PK assessment: Ctrough

    Concentration observed just before treatment administration during repeated dosing (Ctrough)

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  8. PK assessment: AUClast

    Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to time of the last concentration observed above the lower limit of quantification (ie, Clast) (AUClast)

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  9. PK assessment: AUC0 T

    Area under the plasma concentration versus time curve calculated over the dosing interval T (168h or 336h) (AUC0 T)

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

Secondary outcomes

  1. Estimation of absolute bioavailability of isatuximab

    Absolute bioavailability of isatuximab SC, expressed as a percentage, estimated from AUC0-168h obtained after intravenous (IV) and extravascular (EV) administration

    Time frame: Day 8

  2. Overall response rate (ORR)

    ORR is the proportion of patients with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) using the IMWG response criteria

    Time frame: From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)

  3. Duration of response (DOR)

    Time from the date of the first response to the date of first progressive disease (PD) or death, whichever happens first

    Time frame: From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)

  4. Time to response (TTR)

    Time from the date of first study treatment to the first response

    Time frame: From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)

  5. Time to progression (TTP)

    Time from date of first study treatment to date of first documentation of progressive disease

    Time frame: From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)

  6. Overall survival (OS)

    Time from the date of first study treatment to date of death from any cause

    Time frame: From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)

  7. Clinical benefit rate (CBR)

    Proportion of patients with sCR, CR, VGPR, PR or minimal response (MR) according to IMWG criteria

    Time frame: From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)

  8. Progression free survival (PFS)

    Time from date of first study treatment to date of first documentation of progressive disease or death

    Time frame: From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)

  9. Comparison of patient expectations and satisfaction: Patient Expectations and Satisfaction Questionnaires

    Comparison of patient expectations and satisfaction will be assessed using Patient Expectations and Satisfaction Questionnaires before and after subcutaneous (SC) administration, where a score of 1 = not satisfied and a score of 5 = extremely satisfied

    Time frame: Cycles 1 and 2 (28 days per Cycle), and 30 days after last isatuximab administration (up to approximately 14 months after first study treatment administration)

  10. Immunogenicity: Anti drug antibody levels

    Incidence of patients with anti drug antibodies against isatuximab

    Time frame: Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)

  11. Biomarker: Change in CD38 receptor occupancy

    Change in CD38 receptor occupancy from baseline

    Time frame: At screening and at Day 1 of Cycle 2 (28 days per Cycle) (predose); to be stopped once the isatuximab SC dose has been selected.

07

Study locations

14 sites
  • ~Banner MD Anderson Cancer Center Site Number : 8400005
    Gilbert, Arizona 85234, United States
  • City of Hope Site Number : 8400002
    Duarte, California 91010, United States
  • Gabrail Cancer Center Site Number : 8400001
    Canton, Ohio 44718, United States
  • Investigational Site Number : 0360002
    Blacktown, New South Wales 2148, Australia
  • Investigational Site Number : 0360001
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number : 0360004
    Fitzroy, Victoria 3065, Australia
  • Investigational Site Number : 0360003
    Richmond, Victoria 3121, Australia
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 2500001
    Nantes, 44093, France
  • Investigational Site Number : 2500002
    Toulouse, 31059, France
  • Investigational Site Number : 3920002
    Okayama, Okayama-ken 701-1192, Japan
  • Investigational Site Number : 3920001
    Shibuya-ku, Tokyo 150-8935, Japan
  • Investigational Site Number : 7240002
    Santander, Cantabria 39008, Spain
  • Investigational Site Number : 7240001
    Badalona, Catalunya [Cataluña] 08916, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Mar 2024, 55 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 55 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2019
First posted
Aug 6, 2019
StartActual
Aug 6, 2019
Primary completionActual
Mar 27, 2024
CompletionActual
Mar 27, 2024
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04045795
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Aug 6, 2019
Primary completion
Mar 27, 2024
Completion
Mar 27, 2024
Last update
Sep 12, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion